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Background/aim: The aim of the present study was to determine the seroprevalence of Borrelia burgdorferi sensu lato in the city center
and the province of Bolu, Turkey.
Materials and methods: A stratified sampling method was used to determine the study population. A total of 196 blood samples were
collected. A questionnaire was completed by each participant in the study. ELISA was performed and positive serologic results were
confirmed using western blotting. Data were analyzed statistically using the chi-square test.
Results: Seropositivity rates of B. burgdorferi IgM and IgG were determined as 14.8% (29/196) and 13.7% (27/196) respectively by
ELISA. A total of nine serum samples (4.6%) were found positive for IgG, and seven samples (3.8%) were positive for IgM according to
western blotting. Seropositivity rates were found to be higher in people living in rural areas (11.1%), in women (8.3%), in people who
were illiterate (10.0%), in people engaged in agriculture (10.8%), and in the age group of 40–60 years (10.0%). No statistically significant
difference was found between seropositivity rates and survey data.
Conclusion: The seroprevalence of Lyme disease was determined in our region. Detection of endemic regions of Lyme disease with
determination of seropositivity rates will increase the awareness among clinicians about this disease.
Key words: Borrelia burgdorferi, Lyme disease, western blotting

1. Introduction
Lyme disease is a multisystemic disease caused by Borrelia
species, and it is transmitted to humans by ticks of the
species Ixodes. There are three genotypes of the Lyme
disease agent: Borrelia burgdorferi sensu stricto, Borrelia
garinii, and Borrelia afzelii. They are grouped together
under the name B. burgdorferi sensu lato (1). The causative
agent of Lyme disease, B. burgdorferi, was isolated in
1982 (2). Lyme disease is evident in three stages. The
first stage includes erythema migrans (EM) and needs
no serological testing. Diagnosis becomes more difficult
in the second and third stages. In such cases, two-step
diagnosis is necessary. The first step is based on an enzymelinked immunosorbent assay (ELISA) test, and positive
results should be confirmed by Western blot (WB) (3).
Cross-reactions have been found between antibodies to
syphilis, leptospirosis, relapsing fever, varicella, infectious
mononucleosis, and some autoimmune diseases (systemic
lupus erythematosus, rheumatoid arthritis), and ELISA

tests may provide false positive results so the results should
be confirmed by WB (4).
This disease is a common tick-borne zoonosis in
European countries and the United States. In Turkey,
the first cases were reported in 1990 in the Black Sea
and Aegean regions (1). Because Lyme disease is not a
compulsory notification disease in Turkey and due to
confusion with clinical signs of other diseases, the exact
prevalence is not known.
In the present study, the aim was to determine the
seroprevalence of Borrelia burgdorferi sensu lato in the city
center and the province of Bolu, Turkey.
2. Materials and methods
Permission for the study was obtained from the Abant İzzet
Baysal University Clinical Research Ethics Committee, the
Bolu Provincial Health Directorate, and the Association of
Public Hospitals.

* This study was published as a poster at the 6th Congress of Infectious Diseases, 24–27 September 2014, Belgrade, Serbia (Poster No. 395).
** Correspondence: buke06@gmail.com
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2.1. Sample size
Blood samples were collected between August and
October 2013 from the Bolu city center and the Gerede,
Mudurnu, Göynük, Yeniçağa, Seben, Mengen, Dörtdivan,
and Kıbrıscık districts to investigate the seropositivity
rates of Lyme disease. A stratified sampling method was
used to determine the study population. The sample size
was calculated using the following formula:

In this formula, N represents the population size
(the population in the province of Bolu is 276,500), t is
a constant (1.96), p is the a priori assumption of the
population parameter (0.15 according to the results of
recent studies in Turkey), q is equal to 1 – p, and d is the
margin of error (0.05%). The number of research samples
(n) was defined as 196. The sample size was compared for
each district according to population density.
2.2. Questionnaire
Each participant was asked about demographic
information, place of residence, any clinical symptoms of
tick exposure, where they spent the summer, and whether
they dealt with agriculture.
2.3. Laboratory tests
Blood samples of at least 5 mL were taken from patients
and were transferred in appropriate circumstances to the
microbiology laboratory of Abant İzzet Baysal University,
Faculty of Medicine. Blood samples were centrifuged
at 4000 rpm for 10 min and the obtained sera were
stored at –20 °C until analysis. First, a total of 196 blood
samples were investigated for diagnosis of Lyme disease
by the ELISA screening method. A commercial ELISA
kit (Euroimmun, Germany) was used to investigate
IgM against B. burgdorferi, B. afzelii, and B. garinii and
IgG antibody levels against B. burgdorferi, B. afzelii, B.
garinii, and Borrelia vlsE antigens. Results were evaluated
semiquantitatively. At the end of the study, positive and
borderline IgG and IgM results were included in the
second round of study. ELISA serum samples with positive
or borderline results were confirmed using the Borrelia
EUROLINE RN-AT WB kit (Euroimmun). WB IgG and
IgM results were evaluated in accordance with the criteria
in the kit. ELISA and WB tests were performed according
to the manufacturer’s recommendations.
2.4. Statistical analysis
Data analysis was performed using SPSS 17.0 for Windows.
Descriptive statistics were expressed as numbers and
percentages. Differences between groups in terms of
categorical variables were analyzed using the chi-square
and Fisher exact tests. The results were evaluated at a
95% confidence interval and P < 0.05 was accepted as
significant.
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3. Results
The study included 196 individuals; 61.2% of them were
female and 38.8% were male.
According to the ELISA test results 14.8% were positive
(29/196) and 1.0% were borderline (2/196) for IgM, with
13.7% positive (27/196) and 5.1% borderline (10/196) for
IgG. The borderline results from ELISA were negative in
the WB confirmatory test. A total of nine serum samples
(4.6%) were found to be positive for IgG, and seven samples
(3.8%) were positive for IgM according to WB (Tables 1
and 2). One serum sample was positive in both IgG and
IgM ELISA tests. This serum sample was confirmed as
only IgM-positive by the WB test. Both IgM and IgG tests
were not detected as positive in the WB test.
Seropositivity rates were found to be higher in women
(8.3%), in the age group of 40–60 years (10.0%), for those
living in rural areas (11.1%), for people who were illiterate
(10.0%), those who had tick exposure (22.2%), those
engaged in agriculture (10.8%), and those who spent the
summer in rural areas (10.2%). Results of survey data
and distribution of B. burgdorferi seropositivity according
to the WB test are shown in Table 3. No statistically
significant difference was found between seropositivity
rates and survey data.
Demographic characteristics of B. burgdorferi serologypositive cases and serology results are listed in Table 4.
4. Discussion
Lyme disease is endemic to temperate regions of the
northeastern United States and Central and East Europe.
Since becoming a nationally notifiable disease in the
United States in 1991, a total of 248,074 Lyme disease cases
were reported to the Centers for Disease Control. During
Table 1. Comparison of the IgM ELISA and western blot IgM test
results according to the number of patients.

ELISA IgM

Western blot IgM
Negative

Positive

Positive (n = 29)

22

7

Borderline (n = 2)

2

0

Table 2. Comparison of the IgG ELISA and western blot IgG test
results according to the number of patients.

ELISA IgG

Western blot IgG
Negative

Positive

Positive (n = 27)

18

9

Borderline (n = 10)

10

0
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Table 3. Results of survey data from people who gave blood samples and distribution of B. burgdorferi seropositivity according to the
western blot test.

N

%

B. burgdorferi seropositivity*
n

%

P

Gender

Female
Male

120
76

61.2
38.8

10
6

8.3
7.9

0.913

Age group

0–20
21–40
41–60
>60

4
62
50
80

2.1
31.6
25.5
40.8

0
4
5
7

0
6.5
10.0
8.8

0.835

Residence

City
Rural areas

97
99

49.4
50.5

5
11

5.2
11.1

0.128

Educational level

Illiterate
Primary school
Junior high school
University

20
101
52
23

10.2
51.5
26.5
11.7

2
10
4
0

10.0
9.9
7.7
0

0.465

Tick bite history

Yes
No

9
187

4.6
95.4

2
14

22.2
7.5

0.115

After tick contact

Clinical

0

0

0

0

0

Engaged in agriculture

Yes
No

83
113

42.3
57.7

9
7

10.8
6.2

0.240

Location during
summer vacation

Rural areas
City

118
78

60.2
39.8

12
4

10.2
5.1

0.207

*According to IgM or IgG results of the western blot test.

a 15-year study period, the number of cases reported
increased from 9908 in 1992 to 19,931 in 2006 (5). In the
United States, approximately 30,000 cases of Lyme disease
are reported annually. Estimates of the numbers of cases
occurring in Europe are 80,000 per year (6). In Turkey,
seroprevalences have been reported to vary between 7%
and 36% (7–9).
B. burgdorferi infection can result in dermatologic,
musculoskeletal, neurologic, or cardiac abnormalities.
In approximately 70%–80% of cases, patients develop a
characteristic rash, EM, within 30 days of infection. Lyme
disease is diagnosed on the basis of clinical manifestations
and a history of exposure to infected ticks. Laboratory tests
are not required to confirm diagnosis for patients with
characteristic EM. Positive results of the recommended
two-tiered serologic testing can provide confirmation of
infection in patients with musculoskeletal, neurologic, or
cardiac symptoms (4,5).
Bennett et al. reported that in Switzerland 54.5% of the
3443 EM cases between 1997 and 2003 were women and
especially in the age group of 50–74 years (60.1%) (10). It

was reported in Turkey that Lyme positivity was higher in
women in Samsun (11). In our study, the seropositivity rate
was higher in women (8.3%) and 50% of them were in the
age group of 40 to 60 years. As women are more involved
in animal care and work in the fields more compared to
men, their risk of contact with ticks is increased and we
think this affects the emergence of high seropositivity
among females.
Age-related attack rates of Lyme disease show bimodal
distribution according to a study conducted in the United
States. The first peak is from 5 to 9 years (8.9 cases per
100,000 people) and the second most common age range is
55–59 years (7.8 cases per 100,000 people) (5). Considering
the age group in our study, the highest seropositivity rate
was observed in the age group of 40–60 years (10%).
The Lyme disease agents, Ixodes spp. ticks, prefer
forested areas especially and the edges of lakes and rivers
(12). In rural areas, the risk of contact with ticks is greater.
In a study conducted in Spain in 2004, Lyme seropositivity
was 3.45%, with 4.19% reported in rural areas and 2.82%
urban areas (13). In our study, higher seropositivity was
determined among those living in rural areas (11.1% vs.
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Table 4. Demographic characteristics of individuals with positive B. burgdorferi serology and results of serology.
Age

F/M

Tick
contact

Residence

Engaged in
agriculture

ELISA
IgM

ELISA
IgG

WB IgM

WB IgG

1

>60

M

-

Rural area

+

+

-

+ (OspC Bg, OspC Ba)

-

2

20–40

M

+

Rural area

+

+

+

+ (OspC Bg, OspC Ba)

-

3

>60

F

-

Rural area

-

+

-

+ ( OspC Bg, OspC Ba)

-

4

>60

M

-

Rural area

-

+

-

+ ( OspC Bg, OspC Ba, OspC Bb)

-

5

40–60

F

-

City

-

+

-

+ (OspC Bg, OspC Ba)

-

6

20–40

F

-

Rural area

-

+

-

+ (OspC Bg, OspC Ba)

-

7

20–40

F

-

Rural area

+

+

-

+ (OspC Bg)

-

8

>60

F

-

Rural area

+

-

+

-

+ (vlsE Bb, Ba, Bg-p39-p19)

9

>60

F

-

Rural area

+

-

+

-

+ (vlsE Bb, Ba-p39-OspC)

10

40–60

F

-

City

+

-

+

-

+ (vlsE Bb, Ba)

11

>60

M

-

City

-

-

+

-

+ (vlsE Bb-p19-p21)

12

40–60

F

-

City

+

-

+

-

+ (vlsE Bb, Ba, Bg-p39-p83-LBb)

13

40–60

F

-

Rural area

-

-

+

-

+ (vlsE Bb)

14

20–40

M

-

City

-

-

+

-

+ (vlsE Bb-p18-p21)

15

>60

M

+

Rural area

+

-

+

-

+ (vlsE Bb-p83-OspC)

16

40–60

F

-

Rural area

+

-

+

-

+ (vlsE Bb-p39-p21-OspC)

5.2%, respectively). People who spent summers in rural
areas were also found to have higher seropositivity (10.2%)
In our survey, the seropositivity rate was higher in
people who were illiterate (10.0%). Increasing levels of
education increase the level of knowledge in the fight
against ticks and these people are less likely to live in rural
areas or are less likely to be engaged in agriculture.
In North America and Europe, the nymphal stage
of the tick especially is responsible for the emergence of
Lyme disease. Tick exposure is less likely to be noticed as
infected ticks in the nymph stage are small in size, and
the bite does not cause pain and itching. A study in the
United States showed that only 25% remembered a history
of tick bite (14). In our study, tick exposure was stated only
for two of 16 patients seropositive for Lyme disease. This
suggests that tick exposure may not be remembered.
Development of Lyme disease after tick exposure and
the appearance of symptoms varies between regions. In
England, Lyme disease risk varies between 1.2% and 3.7%
after tick exposure (6). Tick exposure was remembered
by nine (4.6%) of 196 people who participated in the
study and only two people (1.0%) had seropositivity. The
reasons for not detecting seropositivity in people who have
tick exposure are thought to be that ticks may not carry
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Lyme factors or recent tick exposure (<1 week) such that
adequate antibody response has not yet occurred.
Due to direct contact with ticks, dealing with
agriculture is a risk factor for B. burgdorferi infection. A
study conducted in Samsun determined that the positive
rate was high in those dealing with agriculture (11). In
our study, the seropositivity rate was higher in people who
dealt with agriculture.
The ELISA serologic method is recommended as a
screening test in epidemiological studies (15). Reagent
antigens used in the ELISA kit cannot be standardized so
discrepancy may be found between the results obtained
in the study. It is reported that vlsE surface protein has
the highest sensitivity among recombinant antigens. The
presence of antibodies against the vlsE immunodominant
antigen is of great importance in the serological diagnosis
of Lyme infection (16,17). In our study, both ELISA and
WB tests included the vlsE recombinant antigen.
Güner et al. determined 98.8% to 100% similarity
with genotypes of Europe (18). Thus, they proved that
the antigen used in diagnostic kits imported from Europe
may be used in the laboratory diagnosis of Lyme disease in
Turkey. In our study, ELISA and WB kits used the antigen
of the European strain.

BUCAK et al. / Turk J Med Sci
Studies indicate that if the immunoblotting assay
includes OspC antigens to detect IgM and vlsE antigen
to detect IgG, the specificity of the diagnostic test is
increased (15,17). In our study, in the WB test, the number
of OspC antigen bands (other bands: p39, vlsE) in IgMpositive patients and the number of vlsE antigen bands in
IgG-positive patients was seen to be more positive (other
bands: OspC, p39, p83, p58, p21, p20, p19, and p18).
In a study conducted in Poland in 2008, Lyme
seropositivity was 6% with the immunoblot method in
healthy people living in urban areas and people working
in rural areas were identified to have 33% seropositivity
(19). In 2001, the seroprevalence of B. burgdorferi was
4.3% in healthy blood donors and 9.3% in forestry workers
according to Hristea et al. (20). In a study conducted
in Italy in 2005, 7.8% were positive for B. burgdorferi
antibodies in the risk group and 4.9% in the control group
according to ELISA, while with the immunoblot method
these values were 7.03% and 3.56%, respectively (21). In
a study conducted in healthy people in Poland using the
ELISA method, seropositivity ranged from 11% to 13%
(22).
Several studies have been conducted to determine
Lyme seropositivity in Turkey. In 1990, the first reports of
Lyme cases were reported from İzmir and Trabzon (1). In
1995, seropositivity was determined as 35.9% by ELISA in
Antalya (7). Studies done in Ankara using ELISA found
that seropositivity was 13% in patients and 7.8% in the
general population in 1999 (9). In 2001 in studies done in
Denizli, Trabzon, and Isparta, seropositivity was found by
ELISA as 18.9%, 6.6%, and 17.07%, respectively (8,23,24).
In 2008 in a study in Düzce, seropositivity was determined
in the risk groups as 10.9% with ELISA and as 1.1% with
WB (2). In the same study, although there was a history of
tick exposure of 51.9%, B. burgdorferi sensu lato infection
was reported to be rare in the area. A study conducted in

the Van region in 2008 found that the seropositivity rate
was 6.3% by ELISA (25). Aslan Başbulut et al. reported
that the seropositivity rate was 4.1% by ELISA and 3.3% by
WB (11). Correlation between seropositivity with a history
of tick exposure was not detected in the same study.
In our study we investigated the Lyme seropositivity
in Bolu Province and its districts. According to our WB
test results, B. burgdorferi sensu lato seropositivity was
detected as 4.6% for IgG and 3.8% for IgM. Our results are
compatible with domestic and foreign data. B. burgdorferi
sensu lato infection cannot be ignored in this province.
Bolu is a province situated in the northwestern region of
Turkey. Most of Bolu consists of forests and lakes, which
may be a risk for tick exposure. Higher seropositivity
rates seen in those living in rural areas, those engaged in
agriculture, and people vacationing in rural areas found
in this study support this hypothesis. Serological tests
are of great importance in the diagnosis of Lyme disease
because of people’s inability to remember a history of tick
exposure, EM lesions cannot always been seen and other
clinical symptoms may be confused with other diseases.
A limited number of studies have been completed about
Lyme disease in Turkey, and the regions where the
disease is endemic are not known yet. Detection of
endemic regions of Lyme disease with determination of
seropositivity rates will increase the awareness among
clinicians about this disease. This research determined the
seroprevalence of Lyme disease in our region. This study
also shed light on other studies to be completed in the
future and will contribute to the creation of seroprevalence
maps in Turkey.
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